The availability of a rule-in-rule-out test for Alzheimer’s disease in primary care settings is likely to drive efficiencies throughout the care continuum.
The US Food and Drug Administration has given clearance to another blood test to help assess Alzheimer’s disease and other ...
GlobalData on MSN
FDA clears Roche’s blood-based test for Alzheimer’s assessment
The US Food and Drug Administration (FDA) has granted clearance for Roche's Elecsys pTau181 test, a blood-based biomarker ...
Elecsys’ approval could help boost the uptake of currently approved Alzheimer’s disease therapies, including Biogen’s ...
The test—developed in collaboration with Eli Lilly and Co.—does not diagnose Alzheimer’s but is designed to rule out the ...
The FDA has granted 510(k) clearance to a blood-based biomarker test indicated for early detection of Alzheimer’s disease and other causes of cognitive decline within a primary care setting, according ...
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (FDA) has cleared its ...
Everyday Health on MSN
New Blood Test to Rule Out Alzheimer’s Gets FDA Clearance
The FDA has cleared Elecsys pTau181, the first blood test for use in primary care to help rule out Alzheimer’s disease in ...
The U.S. Food and Drug Administration has cleared another blood test that could help doctors identify whether memory problems ...
Roche Diagnostics says it has developed blood tests to help rule out a diagnosis of Alzheimer’s disease in the broad population, thus narrowing who might be suffering from the disease. Nearly 7 ...
Basel, 24 December 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for its COVID-19 At-Home ...
The FDA has approved the Elecsys pTau181 test to assist in the initial assessment for Alzheimer's disease and other causes of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback